



Topic	Item	Checklist item description	Reported on Line
<b>Title</b>	1	The diagnosis or intervention of primary focus followed by the words "case report" . . . . .	P1 1-3
<b>Key Words</b>	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" . . .	P2 17-18
<b>Abstract (no references)</b>	3a	Introduction: What is unique about this case and what does it add to the scientific literature? . . . . .	P2 19-P3 15
	3b	Main symptoms and/or important clinical findings . . . . .	P2 4-5
	3c	The main diagnoses, therapeutic interventions, and outcomes . . . . .	P2 5-9
	3d	Conclusion—What is the main "take-away" lesson(s) from this case? . . . . .	P2 11-13
<b>Introduction</b>	4	One or two paragraphs summarizing why this case is unique ( <b>may include references</b> ) . . . . .	P3 13-17
<b>Patient Information</b>	5a	De-identified patient specific information. . . . .	P4 1-3, P7 5-7
	5b	Primary concerns and symptoms of the patient. . . . .	P4 3-4, P7 14-17
	5c	Medical, family, and psycho-social history including relevant genetic information . . . . .	P4 5-6, P7 12-14
	5d	Relevant past interventions with outcomes . . . . .	N/M
<b>Clinical Findings</b>	6	Describe significant physical examination (PE) and important clinical findings. . . . .	P4 6-8, P7 17-19
<b>Timeline</b>	7	Historical and current information from this episode of care organized as a timeline . . . . .	P4 12, P6 7 15, P8 5
<b>Diagnostic Assessment</b>	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys). . . . .	P4 9, 14-18, P7 19-21
	8b	Diagnostic challenges (such as access to testing, financial, or cultural) . . . . .	P10 7-9
	8c	Diagnosis (including other diagnoses considered) . . . . .	P5 20-21, P6 1, P8 14-16
	8d	Prognosis (such as staging in oncology) where applicable . . . . .	P6 20-21, P8 18-19
<b>Therapeutic Intervention</b>	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) . . . . .	P5 8-20, P8 6-18
	9b	Administration of therapeutic intervention (such as dosage, strength, duration) . . . . .	P5 4-5, P8 4-5
	9c	Changes in therapeutic intervention (with rationale) . . . . .	P6 13-16
<b>Follow-up and Outcomes</b>	10a	Clinician and patient-assessed outcomes (if available) . . . . .	P6 20-21, P8 18-19
	10b	Important follow-up diagnostic and other test results . . . . .	P6 21, P7 1-3, P9 2-4
	10c	Intervention adherence and tolerability (How was this assessed?) . . . . .	P9 1-4
	10d	Adverse and unanticipated events . . . . .	N/M
<b>Discussion</b>	11a	A scientific discussion of the strengths AND limitations associated with this case report . . . . .	P10 7-9
	11b	Discussion of the relevant medical literature <b>with references</b> . . . . .	P11, P12
	11c	The scientific rationale for any conclusions (including assessment of possible causes) . . . . .	P12
	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion . . . . .	P13 4-12
<b>Patient Perspective</b>	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received . . . . .	P5 5-7
<b>Informed Consent</b>	13	Did the patient give informed consent? Please provide if requested . . . . .	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>

Article information: <http://dx.doi.org/10.21037/atm-20-2502>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copy editing and may not be referable in the published version.